Pyxis Oncology announced completion of target enrollment in its Phase 1 monotherapy study of MICVO for recurrent/metastatic head and neck cancer, with updated data expected mid-2026. The company also plans to share combination therapy data with KEYTRUDA in late 2026. Financially, Pyxis reported a net loss of $79.6 million for 2025 but holds $68.3 million in cash, sufficient to fund operations into Q4 2026. Leadership changes include the appointment of Thomas Civik as Interim CEO. These developments highlight Pyxis's focus on advancing MICVO and strengthening its clinical and operational capabilities.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum (ETH) has outperformed Bitcoin (BTC) in Q3, driven by a rally sparked by a softer CPI report and strong on-chain metrics. The recent surge pushed ETH above $1,900, triggering significant liquidations in futures positions. However, ETH now fa...
Solana's number of wallets holding tokenized real-world assets (RWAs) has exceeded 300,000, surpassing Ethereum's roughly 200,000 holders. While Solana's RWA value doubled in 2026 to $3.45 billion, Ethereum still leads with $16.3 billion in tokenized...
Baidu's board has approved a plan to convert to a dual-primary listing on the Hong Kong Stock Exchange's Main Board, alongside its existing Nasdaq listing. This move aims to enhance the liquidity of Baidu's shares, broaden its investor base, and prov...
